Members Login

Channels
Special Offers & Promotions
Link Technologies Ltd
Products
Contact Link Technologies Ltd
All articles from Link Technologies Ltd
Maximise Performance and Reduce Development Costs in Oligo Synthesis with New LINK Product Bundles
Oct 19, 2015
LINK Strengthens Presence in Japan with Cosmo Bio and Shigematsu Distribution Agreements
Jul 10, 2015
Link Technologies to exhibit at the Sixth Cambridge Symposium on Nucleic Acids Chemistry and Biology
Aug 17, 2011
Media Partners


LINK, the innovative developer and manufacturer of nucleic acid reagents, is now offering substantial discounts through specially selected product bundles. Responding to its users’ needs for low-cost easy access reagents, LINK has created each bundle to provide scientists with both established and new reagents to evaluate, while saving up to 40% off list price. Users can therefore identify a bundle that covers their area of need...
LINK the innovative developer and manufacturer of nucleic acid reagents, has announced the appointment of a new distributor in Switzerland - Chemie Brunschwig AG. This is LINK’s first formal partnership in Europe, and an important part of its strategy to strengthen Company representation in important market segments, thus increasing access to LINK’s range of innovative reagents for oligo therapeutics and diagnostics. Chemie Brunschwig AG distributes...
LINK’s SAB will identify and prioritise the development of new nucleic acid reagents designed to help researchers synthesise novel oligonucleotide therapeutics and diagnostics. The SAB will also support the management team in identifying other markets where LINK’s chemistry expertise can be beneficial. Brian Sproat (currently Managing Director, Chemconsilium GCV) has worked in the oligonucleotide market since its inception over 30 years ago. A graduate of the...
The growing interest in such compounds is reflective of the current buzz that surrounds research into the enhanced targeting and delivery of nucleotide-based treatments. Such research is vital for the therapeutic industry, wherein accurate targeting and effective uptake of pharmaceutical compounds is essential, not only for positive medicinal value but also to avoid undesirable, potentially dangerous side effects....
Link Technologies Ltd, an ISO 9001:2008 certified specialist oligonucleotide reagent manufacturer, has launched two new modified phosphoramidite ranges to complement its existing extensive portfolio of products to support oligonucleotide synthesis. For triplex, antisense and gene targeting studies, the new RNA-type phosphoramidites provide nuclease resistance and stability, while the new ethyl phosphoramidites improve oligonucleotide stability and delivery into cells, making them ideal for therapeutic applications...